Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9
You may also be interested in...
Big pharma appears increasingly comfortable giving acquired companies operational independence
Neurocrine will seek a new commercialization partner for the insomnia agent indiplon following Pfizer's decision to exit a collaboration for the drug, CEO Gary Lyons said during a June 22 conference call
Greater restrictions on off-label promotions and continued cost pressures are creating an environment ripe for alliances based around single products with split indications, industry executives said during the Windhover Pharmaceutical Strategic Outlook conference in New York March 27-29